191868-55-0

Usage

Physical appearance

White powder

Molecular weight

212.27 g/mol

Medical use

Treatment of high blood pressure, heart failure, and kidney problems

Mechanism of action

Blocks certain enzymes in the body and reduces the production of substances that contribute to the progression of medical conditions

Administration

Orally, in the form of tablets

Dosage

Prescribed based on the specific condition and individual's medical history

Additional research

Potential use in cancer treatment due to its ability to inhibit cellular processes involved in tumor growth

Upstream product

• 191868-54-9 1-(4-cyanophenyl)methanesulfonamide 
• 874-86-2 4-cyanobenzyl chloride 
• 56105-99-8 (4-cyano-phenyl)-methanesulfonyl chloride 

Downstream Products

• 191868-56-1 (R)-N₅-[Amino(nitroimino)methyl]-N-[[4-(aminosulphonyl-methyl)phenyl]methyl]-N₂-(diphenylacetyl)-ornithinamide 

Relevant academic research and scientific papers

Novel synthesis of mafenide and other amino sulfonamides by electrochemical reduction of cyano sulfonamides

Both aliphatic and aromatic amino sulfonamides such as mafenide (1a) were synthesized in good yields (80-86%) by direct electrochemical hydrogenation of the corresponding nitriles in an undivided cell containing a Ni cathode, a Pt anode, and Raney Ni as catalyst (Table 1). The reaction can be performed without external supply of pressurized gas by in situ generation of H2. Slightly elevated temperatures (45°) and low current densities (10 mA/cm2) are favorable conditions for this type of electrochemical nitrile hydrogenation. Our synthetic protocol does not require high-pressure equipment or chemical hazards, is environmentally very friendly, and more economical than traditional methods. The concentration of adsorbed H. radicals on the catalyst surface can be easily controlled by adjusting the electric potential, which may lead to improved product selectivity and, at the same time, reduces the risk of explosion and fire.

Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them

NPY-antagonistic compounds of the formula STR1 Exemplary are: (A) (R)-N-[[4-(Aminocarbonylaminomethyl)phenyl]methyl]-N 2-bis(4-hydroxyphenyl)acetyl]-argininamide-trifluoracetate;(B) (R)-N-[[4-(Aminocarbonylaminomethyl)phenyl]methyl]-N 2-[bis(4-chlorphenyl)acetyl]-argininamide-trifluoracetate;(C) (R)-N-[[4-Aminocarbonylaminomethyl)phenyl]methyl]-N 2-(diphenylacetyl)-argininamide-trifluoracetate;(D) (R)-N 2-(Diphenylacetyl)-N-[[4-(ethoxycarbonylmethylamino-carbonylaminomethyl) phenyl]methyl]-argininamide-trifluoroacetate;(E) (R,S)-N 5-(Aminoiminomethyl)-N 2-(diphenylacetyl)-N-[(4-hy-droxyphenyl)methyl]-N 5-methyl-ornithinamide-hydrochloride; (F) (R)-N-[[4-(Aminocarbonylmethyl)phenyl]methyl]-N 2-(diphenyl-acetyl)-argininamide-diacetate;(G) (R)-N. sup. 2-(Diphenylacetyl)-N-[[4-(ethylaminocarbonylamino-methyl)-phenyl]methyl]-argininamide-bis-(trifluoroacetate); and,(H) (R)-N. sup.2-(Diphenylacetyl)-N-[[4-(ethoxycarbonylamino-carbonylaminomethyl) phenyl]methyl]-argininamide-trifluoroacetate.